Hulse, G.K., Improving clinical outcomes for naltrexone as a management of problem alcohol use, Br. J. Clin. Pharmacol., 2013, vol. 76, no. 5, pp. 632—641. https://doi.org/10.1111/j.1365-2125.2012.04452.x

Article  CAS  PubMed  Google Scholar 

Mroziewicz, M. and Tyndale, R.F., Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment, Addict. Sci. Clin. Pract., 2010, vol. 5, no. 2, pp. 17—29.

PubMed  PubMed Central  Google Scholar 

Ahmed, S., Zhou, Z., Zhou, J., et al., Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine, Genomics, Proteomics Bioinf., 2016, vol. 14, no. 5, pp. 298—313. https://doi.org/10.1016/j.gpb.2016.03.008

Article  CAS  Google Scholar 

Crisafulli, C., Romeo, P.D., Calabro, M., et al., Pharmacogenetic and pharmacogenomic discovery strategies, Cancer Drug Resist., 2019, vol. 2, no. 2, pp. 225—241. https://doi.org/10.20517/cdr.2018.008

Article  PubMed  PubMed Central  Google Scholar 

Broglio, K. and Matzo, M., CE: acute pain management for people with opioid use disorder, Am. J. Nurs., 2018, vol. 118, no. 10, pp. 30—38. https://doi.org/10.1097/01.NAJ.0000546378.81550.84

Article  PubMed  Google Scholar 

Shen, W.W., Anticraving therapy for alcohol use disorder: a clinical review, Neuropsychopharmacol. Rep., 2018, vol. 38, no. 3, pp. 105—116. https://doi.org/10.1002/npr2.12028

Article  PubMed  PubMed Central  Google Scholar 

Krupitsky, E., Zvartu, E., Blokhina, E., et al., Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence, Drug Alcohol Depend., 2013, vol. 132, no. 3, pp. 674—680. https://doi.org/10.1016/j.drugalcdep.2013.04.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zangiabadian, M., Golmohammadi, S., Nejadghaderi, S.A., et al., The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: a systematic review and meta-analysis, Front. Psychiatry, 2022, vol. 13, p. 1003257. https://doi.org/10.3389/fpsyt.2022.1003257

Article  PubMed  PubMed Central  Google Scholar 

Resnick, R.B., Volavka, J., Freedman, A.M., et al., Studies of EN-1639A (naltrexone): a new narcotic antagonist, Am. J. Psychiatry, 1974, vol. 131, no. 6, pp. 646—650. https://doi.org/10.1176/ajp.131.6.646

Article  CAS  PubMed  Google Scholar 

Altshuler, H.L., Phillips, P.E., and Feinhandler, D.A., Alteration of ethanol self-administration by naltrexone, Life Sci., 1980, vol. 26, no. 9, pp. 679—688. https://doi.org/10.1016/0024-3205(80)90257-X

Article  CAS  PubMed  Google Scholar 

Heyser, C.J., Moc, K., and Koob, G.F., Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats, Neuropsychopharmacology, 2003, vol. 28, no. 8, pp. 1463—1471. https://doi.org/10.1038/sj.npp.1300175

Article  CAS  PubMed  Google Scholar 

Verholleman, A., Victorri-Vigneau, C., Laforgue, E., et al., Naltrexone use in treating hypersexuality induced by dopamine replacement therapy: impact of OPRM1 A/G polymorphism on its effectiveness, Int. J. Mol. Sci., 2020, vol. 21, no. 8, p. 3002. https://doi.org/10.3390/ijms21083002

Article  PubMed  PubMed Central  Google Scholar 

Bosco, D., Plastino, M., Colica, C., et al., Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease, Clin. Neuropharmacol., 2012, vol. 35, no. 3, pp. 118—120. https://doi.org/10.1097/WNF.0b013e31824d529b

Article  CAS  PubMed  Google Scholar 

Kranzler, H.R. and van Kirk, J., Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis, Alcohol Clin. Exp. Res., 2001, vol. 25, no. 9, pp. 1335—1341.

CAS  PubMed  Google Scholar 

Rösner, S., Hackl-Herrwerth, A., Leucht, S., et al., Opioid antagonists for alcohol dependence, Cochrane Database Syst. Rev., 2010, vol. 12, p. CD001867.pub3. https://doi.org/10.1002/14651858.CD001867.pub3

Srisurapanont, M. and Jarusuraisin, N., Opioid antagonists for alcohol dependence, Cochrane Database Syst. Rev., 2005, vol. 1, p. CD001867.pub2. https://doi.org/10.1002/14651858.CD001867.pub2

Streeton, C. and Whelan, G., Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials, Alcohol Alcohol., 2001, vol. 36, no. 6, pp. 544—552. https://doi.org/10.1093/alcalc/36.6.544

Article  CAS  PubMed  Google Scholar 

Fals-Stewart, W. and O’Farrell, T.J., Behavioral family counseling and naltrexone for male opioid-dependent patients, J. Consult. Clin. Psychol., 2003, vol. 71, no. 3, pp. 432—442. https://doi.org/10.1037/0022-006x.71.3.432

Article  PubMed  Google Scholar 

Chamorro, A.-J., Marcos, M., Miron-Canelo, J.-A., et al., Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis, Addict. Biol., 2012, vol. 17, pp. 505—512. https://doi.org/10.1111/j.1369-1600.2012.00442.x

Article  CAS  PubMed  Google Scholar 

Kim, S.-G., Kim, C.-M., Choi, S.-W., et al., A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients, Psychopharmacology, 2009, vol. 201, no. 4, pp. 611—618. https://doi.org/10.1007/soo213-008-1330-5

Article  CAS  PubMed  Google Scholar 

Porter, S.J., Somogyi, A.A., and White, J.M., Kinetics and inhibition of the formation of 6-beta-naltrexol from naltrexone in human liver cytosol, Br. J. Clin. Pharmacol., 2000, vol. 50, no. 5, pp. 465—471. https://doi.org/10.1046/j.1365-2125.2000.00281.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taqi, M.M., Faisal, M., and Zaman, H., OPRM1 A118G polymorphisms and its role in opioid addiction: implication on severity and treatment approaches, Pharmgenomics Pers. Med., 2019, vol. 12, pp. 361—368. https://doi.org/10.2147/PGPM.S198654

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kranzler, H.R., Armelli, S., Feinn, R., et al., Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers, J. Consult. Clin. Psychol., 2004, vol. 72, no. 2, pp. 317—327. https://doi.org/10.1037/0022-006X.72.2.317

Article  PubMed  Google Scholar 

Alshogran, O.Y. and Zayed, A.L., A simple HPLC-MS/MS method for quantification of naltrexone and 6-beta naltrexol: an application to effect of uremic toxins on metabolic reduction, J. Young Pharm., 2019, vol. 11, no. 3, pp. 261—265. https://doi.org/10.5530/jyp.2019.11.53

Article  CAS  Google Scholar 

Penning, T.M., The aldo-keto reductases (AKRs): overview, Chem. Biol. Interact., 2015, vol. 234, pp. 236—246. https://doi.org/10.1016/j.cbi.2014.09.024

Article  CAS  PubMed  Google Scholar 

Penning,T.M. and Drury, J.E., Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms, Arch. Biochem. Biophys., 2007, vol. 464, no. 2, pp. 241—250. https://doi.org/10.1016/j.abb.2007.04.024

Article  CAS  PubMed  PubMed Central  Google Scholar 

Penning, T.M., Wangtrakuldee, P., and Auchus, R.J., Structural and functional biology of aldo-keto reductase steroid-transforming enzymes, Endocr. Rev., 2019, vol. 40, no. 2, pp. 447—475. https://doi.org/10.1210/er.2018-00089

Article  PubMed  Google Scholar 

Zeng, C.M., Chang, L.L., Ying, M.D., et al., Aldo-keto reductase AKR1C1-AKR1C4: functions, regulation, and intervention for anti-cancer therapy, Front. Pharmacol., 2017, vol. 8, p. 119. https://doi.org/10.3389/fphar.2017.00119

Article  CAS  PubMed  PubMed Central  Google Scholar 

Platt, A., Xia, Z., Liu, Y., et al., Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases, Pharmacogenet. Genomics, 2016, vol. 26, no. 8, pp. 370—380. https://doi.org/10.1097/FPC.0000000000000226

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krupitsky, E., Zvartau, E., Blokhina, E., et al., Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence, Arch. Gen. Psychiatry, 2012, vol. 69, no. 9, pp. 973—981. https://doi.org/10.1001/archgenpsychiatry.2012.1a